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1. Introduction  
REM sleep behavior disorder (RBD) is characterized by dream-enacting behaviors and 
unpleasant dreams, and presents a risk for self-injury and harm to others due to abnormal 
REM sleep during which control of muscle tonus is lacking (REM sleep without atonia) 
(Schenck et al., 1986; Schenck et al., 2002; American Academy of Sleep Medicine 2005). 
RBD is a heterogeneous disease entity consisting of a variety of manifestations (Schenck et 
al., 2002; Gagnon et al. 2006; Postuma et al., 2006, 2009; Maetzler et al., 2009). Idiopathic 
RBD (iRBD), which develops in middle age or later and progresses chronically, in 
particular is a common clinical manifestation of Lewy body-related syndrome and is 
regarded as a clinical entity from pathological aspects. For example (Table 1), it has been 
elucidated that iRBD is often accompanied by soft motor signs, olfactory and color 
identification deficits, decreased cardiovascular and respiratory changes between REM 
and Non-REM sleep, reduced cardiac 123I-metaiodobenzylguanidine (123I-MIBG) uptake, 
impairment of visual memory and visuo-spatial construction revealed by 
neuropsychological testing, EEG slowing during wakefulness or sleep, and decreased 
strial dopaminergic innervation and reduced pre-synaptic strial dopamine transporter 
binding on SPECT or positron emission topography (PET) scans, which are considered as 
non-motor symptoms of Parkinson’s disease (PD) (Becker et al., 2002; Gagnon et al., 2006; 
Miyamoto et al., 2006; Miyamoto et al., 2008). Furthermore, despite the limited number of 
pathological reports on iRBD, the characteristics of iRBD have been supported to  
have a close relationship with Lewy body pathology (Boeve et al., 2007). Therefore, 
additional clinical features that could distinguish iRBD with Lewy body-related  
alpha-synucleinopathies from iRBD due to other causes would be helpful in clinical 
practice.  
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Transcranial ultrasound imaging of the substantia nigra  
Olfactory dysfunction 
Impairment of visual functions  
Visualization of postganglionic sympathetic cardiac neurons by 123I-
metaiodobenzylguanidine (MIBG) scintigraphy 
MRI 
Cognitive decline 
Affective symptoms 
Motor testing 
Sleep disturbance 
REM sleep behavior disorder  
Daytime sleepiness 
Fatigue 
Insomnia 
Table 1. Early diagnosis of Parkinson’s disease 
2. Polysomonography 
Loss of REM sleep atonia is the essential hallmark of RBD. Abnormal activity of phasic REM 
sleep components is essential for the induction of dream-enacting behaviors during REM 
sleep in iRBD. Motor-behavioral episodes in RBD are significantly more likely to occur in 
association with phasic than with tonic periods of REM sleep (Figure 1). Excessive tonic and 
phasic EMG activity during REM sleep has been shown to increase over time in subjects 
with iRBD (Iranzo et al. 2009). This finding suggests that, in subjects with iRBD, there is an 
underlying progressive pathologic process damaging the brainstem structures that 
modulate REM sleep. Out of a group of potential predictive markers, higher % tonic EMG 
activity was the most predictive of development of PD (Postuma et al. 2009).  
 
 
Fig. 1. Stage of RWA in a patient idiopathic REM sleep behavior disorder. The recording 
shows sustained elevation of submental and tibialis anterior (TA) EMG concomitant with 
phasic EMG elevation. EEG bears the characteristic feature of REM sleep, low voltage 
activity with mixed frequency, and EOG demonstrates clusters of rapid eye movements. 
RWA, REM sleep without atonia; EOG, electrooculogram. 
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3. Olfactory dysfunction 
Olfactory disturbance is present in most PD or pure autonomic failure (PAF) cases (Doty et al., 
1995; Goldstein et al., 2009; Silverira-Moriyama et al., 2009). The deficit in olfaction in PD 
contrasts with previous reports of preserved or only mildly reduced olfaction in patients with 
atypical parkinsonism such as a tauopathy or multiple system atrophy (MSA) (Doty et al., 
1993; Wenning et al., 1995). In dementia patients, neuropathologic studies reported neuronal 
alterations in several subcortical structures such as the olfactory tract/bulb, anterior olfactory 
nucleus, orbito-frontal cortex, hippocampus, and amygdala in the olfactory system (Hubbard 
et al., 2007). Olfactory abnormalities have been reported in Alzheimer’s disease (AD), but 
anosmia appears to be common in dementia with Lewy bodies (DLB) but not in pure AD 
(McShane et al., 2001). A Lewy body variant of AD had an increased frequency of anosmia 
compared with “pure” AD (Olichney et al., 2005). Furthermore, olfactory impairment is more 
marked in patients with mild dementia with Lewy bodies than in those with mild AD 
(Williams et al., 2009). In addition to reduced odor identification prior to the onset of PD, 
olfactory dysfunction has been frequently recognized in patients with incidental Lewy body 
disease (ILBD) (Ross et al. 2006). Also, neuropathological olfactory bulb alpha-synuclein has 
high specificity and sensitivity for Lewy body formation in confirmed cases of PD and DLB 
(Beach et al., 2009). On the basis of pathological studies of a large number of autopsy cases, 
Braak et al. proposed a hypothesis as to the onset and advancement pattern of PD in that the 
disease developed from the medulla and olfactory bulb and extended to the pons and 
substantia nigra (SN) (Braak et al., 2003). In the Honolulu-Asia Aging Study of Japanese 
Americans, 2,267 males without PD and dementia at the time of olfaction testing were 
followed-up, and more subjects who developed olfactory dysfunction in the first 4-year 
follow-up period developed PD than those who did not develop olfactory dysfunction (Ross et 
al., 2008). Another study clinically followed patients with idiopathic hyposmia to determine 
the percentage of patients who developed idiopathic PD after a 4-year interval. 7% of the 
individuals with idiopathic hyposmia had developed clinical PD, and 13% presented with 
abnormalities of the motor system. (Haehner et al., 2007). In a prospective study involving 
first-degree relatives of PD patients, a low score on three olfactory processing tasks was 
associated with an increased risk of developing PD within 5 years (Ponsen et al., 2009). The 
point of view that reduced odor identification is manifested at the very beginning of the 
development of PD has been supported. These reports indicate that the rhinencephalon may 
be an area of selective vulnerability for alpha-synuclein accumulation (Sengoku et al., 2008) 
and iRBD that develops in middle age or after progresses mostly to Lewy body diseases 
among synucleinopathies such as PD and DLB, which have some pathological features in 
common. In Fantini’s and Postuma’s cohorts (Fantini et al., 2006; Postuma et al., 2006), the 
olfactory deficit as revealed by the University of Pennsylvania Smell Identification Test found 
in most iRBD patients shares similarities with that described in PD. We also found that 
reduced odor identification as revealed by the Odor Stick Identification Test for Japanese were 
similar in patients with iRBD and PD and distinct from a control group (Miyamoto et al., 2009). 
4. Color discrimination 
Color vision abnormalities are among the non-motor clinical characteristics of PD (Prise et 
al., 1992; Büttner et al., 1995), and impairments in color discrimination and contrast 
sensitivity in PD are progressive over time (Diederich et al., 2002). The severity of the axial 
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motor symptoms has been shown to be more closely related to visual dysfunction than 
mental function. Most patients with PD showed more marked impairment along the red-
green axis than the blue-yellow axis (Oh et al., 2011), and this pattern contrasts with that 
typically seen in aging-predominant blue-yellow axis deficiency (Archibald et al., 2009). 
Color discrimination deficits also have been reported in iRBD, a potential forerunner of PD 
(Postuma et al., 2008). In their prospective study, they found that two potential preclinical 
markers of neurodegeneration, olfaction and color vision, indeed identify early-stage 
synucleinopathy-mediated neurodegenerative diseases (Figure 2). Compared to those 
remaining diseases free, patients destined to develop disease had poorer baseline olfaction 
and color vision. In most cases, abnormalities are measurable up to at least 5 years before 
disease onset , and progress slowly in the preclinical stages (Postuma et al., 2011). 
 
 
Fig. 2. Farnsworth-Munsell 100 Hue test (FMT).  
The total error score for a patient with iRBD or PD was higher than that of a control subject. 
iRBD, idiopathic REM sleep behavior disorder. PD, Parkinson’s disease. 
5. Magnetic resonance imaging studies 
We detected an increase (compared with reference values from another institution) in the 
choline/creatine ratio on protein magnetic resonance spectroscopy (1H-MRS) in the pons of 
a 69-year-old man with iRBD. Since other ratios were normal, the investigators interpreted 
these findings as demonstrating functional impairment at the cell membrane level 
(Miyamoto et al., 2000).  Iranzo and coworkers performed 1H-MRS in a larger sample of 
patients with iRBD (n = 15) to determine if midbrain or pontine tegmentum abnormalities 
could be detected compared with matched controls (n = 15) (Iranzo et al., 2002). No 
significant differences in N-acetylaspartate/creatine, choline/creatine, and 
myoinosito/creatine ratios were found between patients and controls, which they 
interpreted as suggesting that marked mesopontine neuronal loss or 1H-MRS-detectable 
metabolic disturbances do not occur in iRBD. Recently, Unger and coworkers described 
diffusion tensor imaging changes in patients with iRBD (Unger et al., 2010). They found 
important microstructural abnormalities in the white matter of the brain stem, as well as in 
the right SN, olfactory region, left temporal lobe, fornix, and the right visual stream of 
patients with iRBD (n =12), which are known to be involved in REM sleep regulation 
and/or to indicate neurodegenerative pathology in early PD. In another recent study 
(Scherfler et al., 2010), Statistical Parametric Mapping localized significant decreases in 
Control iRBD PD
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fractional anisotropy in the tegmentum of the midbrain and rostral pons and increases in 
mean diffusivity within the pontine reticular formation overlapping with a cluster of 
decreased fractional anisotropy in the midbrain. Voxel-based morphometry revealed 
increases in gray matter densities in both hippocampi of iRBD patients. A concomitant 
fractional anisotropy decrease and mean diffusivity increase are thought to be correlates of 
neuronal and myelin damage leading to depletion of barriers restricting water molecular 
motion. As a result, anisotropy, which is a measure of the degree of alignment of cellular 
structures within fiber tracts, decreases and the magnitude of diffusion, a measure of 
extracellular fluid volume, increases. Cortical gray matter volume increases are likely to be 
related to sprouting of new connections, dendritic spine growth, and modification in the 
strength of existing connections. Their findings are in line with a [99m]Tc-ethylene 
cysteinate dimer SPECT study (Mazza et al., 2006) reporting increased cerebral blood flow in 
the hippocampus of patients with iRBD suggesting hypermetabolism, which would fit the 
concept of increased gray matter volume in the hippocampus. Further functional imaging 
studies are warranted to investigate the pathogenesis beyond the structural gray matter 
density changes and cerebral blood flow increases in the hippocampus in iRBD. 
6. Transcranial ultrasound sonography  
Enlarged SN hyperechogenicity (SN+) assessed by transcranial ultrasound sonography 
(TCS) is present in about 90% of PD patients, independent of age and disease stage. SN+ 
may ultimately be considered an imaging marker for disease progression in PD. It also may 
be useful as a screening tool to detect individuals at risk for developing PD.  
Using age-corrected data, motor signs of PD were shown to begin when the decrease in the 
percentage of [123I] FP-CIT binding ratios in the putamen was 46-64% (Booij et al., 2001). 
There was a significant correlation between the extension of the echogenic SN area and 
striatal β-CIT binding( Weise et al., 2009). They discussed the possibility that extension of 
SN echogenicity may be a consequence of degeneration of dopaminergic neurons in the SN 
rather than an independent and mechanistically unrelated phenomenon. 18Fluoro-DOPA 
uptake was lowest in patients with PD followed by individuals with SN+ and finally 
healthy controls without SN+ (Behnke et al., 2009). On the other hand, a lack of correlation 
between SN echogenicity and striatal FP-CIT uptake was found (Spiegel et al., 2006; Doepp 
et al., 2008). They hypothesized that the pathogenic substrate of SN+ is different from that 
associated with degeneration of dopaminergic SN projection neurons. Furthermore, in 
asymptomatic and symptomatic parkin mutation carriers, echogenic SN areas were found to 
be enlarged(Walter et al., 2004). Brain parenchyma sonography demonstrated SN+ in 
concordance with abnormal nigrostriatal 18F-dopa PET in all symptomatic and 3 
asymptomatic Parkin mutation carriers. Thus, they suggested SN+ as an early marker for 
detection of preclinical parkinsonism. Moreover, SN+ is a stable marker because the area of 
echogenicity is not related to the disease stage and was found not to change during the 
course of disease progression over a 5-year follow-up period (Berg et al., 2005). Thus, SN+ 
may reflect a pathogenic process that initiates the degeneration of dopaminergic neurons 
but does not reflect its morphological substrate. 
The clinical interest and utility of the findings of our study (Figure 3) are that 
hyperechogenic alterations in the area of the SN may be suggestive of the existence of 
preclinical dopaminergic dysfunction and of an underlying neurodegenerative disorder 
associated with nigrostriatal dysfunction in those with iRBD. Approximately 9% of the 
healthy population exhibits the same ultrasound signal, which is found in those with 
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subclinical impairment of the nigrostriatal system as detected by 18F-labeled dopa PET 
examinations (Berg et al., 1999; Berg et al., 2002; Behnke et al., 2009). SN+ subjects have an 
approximately twofold probability for the combined occurrence of the risk markers for 
impaired motor performance and hyposmia versus those with SN－ and SN+ is more 
regularly observed in subjects with higher Unified Parkinson's Disease Rating Scale 
(UPDRS) motor scores, in particular in subjects with UPDRS scores above 3 (Berg et al., 
2010). This observation indicates that the ultrasound feature may serve as a marker for 
nigrostriatal vulnerability in affected healthy persons or in those in the premotor phase of 
PD. The frequency of iRBD patients with SN+ was 37.3% (Stockner et al., 2009) or 41.2% 
(Iwanami et al., 2010). The finding of an increased frequency of SN+ in a subgroup of 
individuals with an a priori increased risk for PD supports the potential role of SN+ as a risk 
marker for PD. Our recent study compared FMT-PET findings between patients with iRBD 
grouped according to the presence or absence of SN+ (Miyamoto et al., in press). 6-[18F]-
FMT is also a good substrate for aromatic L-amino acid decarboxylase (AADC) but is not 
metabolized by catechol-O-methyl-transferase . Thus, 6-[18F]-FMT uptake has approximately 
twice the sensitivity of 6-[18F]fluoro-L-dopa uptake and more fully represents the extent of 
AADC activity (Asari et al., 2011). We found that enlarged SN+ in patients with iRBD may 
be suggestive of nigrostriatal dopaminergic dysfunction as determined by FMT-PET. 
However, as there was no significant correlation between the area of SN+ and the degree of 
6-[18F]-FMT uptake, it may be that two parameters have different characteristics from each 
other. In other words, the area of SN echogenicity is thought to be a stable marker, whereas 
dopaminergic tracer uptake changes with time. In a recent study (Iranzo et al., 2010), 19% of 
43 patients developed a neurodegenerative syndrome such as PD, DLB or MSA 2.5 years 
after TCS and 123I-FP-CIT SPECT and they noted that combined use of 123I-FP-CIT SPECT 
and TCS is a potential strategy for early identification of iRBD patients who are at risk for 
development of a synucleinopathy. They also reported that one case of iRBD who developed 
MSA had decreased striatal 123I-FP-CIT uptake and normal echogenic SN, and that this 
discrepancy might be explained by the fact SN+ is less frequent in MSA than in PD and 
DLB. Even those individuals with iRBD with a normal echogenic SN may  be at risk of 
developing MSA. Therefore we need to follow up iRBD patients with regard to the risk for 
developing to not only PD or DLB but also MSA.  
 
 
Fig. 3. Typical examples of transcranial ultrasound images of the midbrain encircled by 
dotted lines in control, iRBD and PD patients. The area of enlarged hyperechogenic 
substantia nigra signal was encircled on the ipsilateral side for planimetric measurement.  
iRBD, idiopathic REM sleep behavior disorder. PD, Parkinson’s disease. 
Control RBD PD
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7. PET and SPECT 
Cognitively normal persons with dream-enactment behavior have a reduced cerebral 
metabolic rate of glucose (CMRgl) in brain regions known to be metabolically affected by 
DLB and AD (parietal, temporal, and posterior cingulate cortexes) and in several other 
regions, including the anterior cingulate cortex. The authors interpreted these findings as 
supporting further study of dream-enactment behavior as a possible risk factor for the 
development of DLB (Caselli et al., 2006). In another recent study, four patients were found 
to have diffuse areas of reduced CMRglc, predominantly in the occipital lobe, which is the 
preferentially affected region in DLB patients. In contrast, in five patients no such occipital 
hypometabolism was shown; instead, in those five patients hypometabolism was evident in 
the left anterior cingulate gyrus (Broadmann area (BA) 24), right frontal lobe (BA 32) and 
right anterior temporal lobe (BA 38), which are the preferentially affected regions in PD 
rather than DLB (Fujishiro H et al., 2010). The variability in the [18F]–FDG PET scans of the 
present subjects raised the possibility that some iRBD patients with particular patterns may 
go on to develop PD or DLB. In terms of early intervention, it is important to determine 
which patterns on the [18F]–FDG PET scans of iRBD patients are suggestive of underlying 
prodromal DLB or PD. 
A single photon emission computed tomography imaging study showed that PD patients 
with visual hallucinations had perfusion reductions in the bilateral inferior parietal lobule, 
inferior temporal gyrus, precuneus gyrus and occipital cortex (Matsui et al., 2006). In a 
cerebral SPECT study (Shirakawa et al., 2002) that compared iRBD patients with a control 
group, a statistically significant decrease in blood flow was observed in the upper portion of 
the frontal lobe on the left and right sides and the pons in the iRBD group. According to 
another study (Mazza et al., 2006), there was increased perfusion in the pons and putamen 
bilaterally and in the right hippocampus, and decreased perfusion in frontal and 
temporoparietal cortices. They concluded that the similarity between the distribution of 
perfusional impairments found in iRBD and those observed in patients with early PD argues 
for a common pathophysiologic mechanism for these syndromes in at least the initial stages 
of these conditions. Our recent study (Hanyu et al., 2010), found decreased regional cerebral 
blood flow in the parietooccipital lobe (precuneus), limbic lobe, and cerebellar hemispheres 
in patients with iRBD. Such perfusion abnormalities are also common in patients with 
confirmed alpha-synucleinopathies (PD, DLB, or MSA).  
Thus, based on these findings, as with [18F]–FDG PET or SPECT findings in iRBD, a close 
relationship is indicated between PD and DLB, although the phenomenon is not observed 
constently with regard to the pathology of iRBD. The results of [18F]–FDG PET or SPECT 
studies suggest that iRBD can be a presymptomatic stage of alpha-synucleinopathies. 
Striatal binding of DTBZ-PET (Albin et al., 2000) was reduced in iRBD subjects compared 
with control subjects, suggesting reduced dopaminergic SN neuron numbers. 123I-IPT 
SPECT (Eisensehr et al., 2000) demonstrated a reduction of striatal dopamine transporter 
binding in iRBD which is indicative of a presynaptic dopaminergic deficit such as in PD 
patients. In a recent study (Kim et al., 2010), the dopamine transporter density of the 
subregions in the majority of RBD patients remained above the lower normal limit, although 
there was a significant group difference in CIT binding in the putamen between RBD and 
control subjects. In contrast, CIT binding in each region in most of the PD patients was 
below the normal range. In our study (Figure 4), a 6-[18F]-fluoro-meta-tyrosine PET 
(FMT/PET) template was superimposed onto each individual brain MRI for PD, iRBD, and 
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control subjects. Regions of interest (ROIs) for the striatum and cerebellum were placed over 
each brain template. ROIs were manually drawn on the FMT/PET after overlapping with 
each brain MRI, and the striatal ROI was divided into the putamen and caudate. We 
proposed that FMT-PET imaging could assess the level of the presynaptic dopaminergic 
nerve for iRBD, PD, and control subjects. IRBD patients had no signs of parkinsonism and 
had neuroimaging evidence of an almost intact striatal dopaminergic innervation such as in 
controls. In contrast, PD patients have parkinsonism by definition and have loss of striatal 
dopaminergic innervation, as evidenced by decreased striatal uptake. We followed the 
present case by PET immediately after development of iRBD and at 2.5 years after the first 
scan (Miyamoto et al., 2010) . Nigrostriatal presynaptic dopaminergic function was normal 1 
year after the diagnosis of iRBD and decreased by 4～6% per year, which is similar to that in 
PD (Nurmi et al., 2003). Nigrostriatal dopaminergic degeneration could be a part of the 
pathogenesis of RBD, but is not essential for the development of RBD.  
 
 
Fig. 4. 6-[18F]-fluoro-meta-tyrosine PET (FMT/PET) template superimposed onto each 
individual brain MRI for PD, iRBD, or control subjects. IRBD patients have no signs of 
parkinsonism and have neuroimaging evidence of almost intact striatal dopaminergic 
innervation such as in controls. Nor do they have reduced uptake such as in PD. 
8. Cardiac 123I-MIBG scintigraphy 
There is evidence that 123I-MIBG cardiac uptake is markedly reduced in patients with Lewy 
body diseases such as PD, DLB, and PAF (Courbon et al., 2003; Kashihara et al., 2006; 
Yoshita et al., 2006). It was reported that cardiac 123I-MIBG imaging could distinguish 
between clinically diagnosed DLB and AD with high levels of sensitivity and specificity 
(Yoshita et al., 2006) . Interestingly, pathological findings occur even in patients with DLB 
who have no parkinsonism. Since PAF patients do not have parkinsonism or decreased 
striatal dopaminergic innervation, and since cardiac noradrenergic denervation occurs in 
both diseases, the pathogenetic mechanisms of cardiac noradrenergic denervation in Lewy 
body diseases differ from those producing parkinsonism and nigrostriatal dopaminergic 
denervation (Goldstein et al., 2009). A reduction in 123I-MIBG uptake in sympathetic 
terminals was observed in cases with early-phase PD and ILBD irrespective of the presence 
or absence of remarkable autonomic nerve injury (Courbon et al., 2003). As pathological 
evidence (Orimo et al., 2007; Orimo et al., 2008; Fujishiro et al., 2008), it has been proven that 
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the Lewy body is present in cardiac sympathetic nerve postganglionic fibers, and it has been 
suggested that Lewy body-related pathology potentially causes severe denervation and 
reduced 123I-MIBG uptake in the cardiac postganglionic sympathetic nerves. The 123I-
MIBG studies showed markedly decreased cardiac uptake in PD, DLB and PAF, which is a 
common feature of Lewy body diseases(Courbon et al., 2003; Kashihara et al., 2006; Yoshita 
et al., 2006). 
We reported markedly reduced cardiac 123I-MIBG uptake in iRBD as well as in PD or DLB 
(Miyamoto et al., 2006; Miyamoto et al., 2008)(Figure 5). In our recent case report (Miyamoto 
et al., 2009), we described a small subset of iRBD patients who have relatively preserved 
uptake at RBD onset, but which then becomes lost over the follow-up period. If RBD 
precedes MSA, 123I-MIBG uptake is preserved over years; on the other hand, in iRBD 
patients, progression in the reduction in 123I-MIBG uptake occurs over years. 
 
 
Fig. 5. Idiopathic RBD subject displayed reductions in cardiac 123I-MIBG uptake (arrows) in 
contrast to a control subject. Uptake was also markedly reduced in a PD or DLB subject 
(arrows).  
9. iRBD and relevance to Lewy body pathology  
Men over the age of 50 years who have iRBD are at very high risk for future PD, DLB or 
MSA several years after the onset of RBD (Schenck et al., 1996; Iranzo et al., 2006; Postuma et 
al., 2009). Neuropathologic studies at autopsy of cases that had been diagnosed with RBD 
while alive showed that every case had Lewy bodies (Boeve et al., 2007). For example, 
cognitive abnormalities appeared 15 years after the onset of RBD and probable DLB was 
diagnosed, and eventually the presence of Lewy bodies was confirmed pathologically 
(Turner et al. 2000). Patients with ILBD were shown to have nigrostriatal pathological 
features that are intermediate between those in pathologically normal persons and those 
with PD ( DelleDonne et al., 2008 ). Among the study participants with ILBD, decreased 
striatal dopaminergic immunoreactivity was documented for both tyrosine hydroxylase 
(TH) and vesicular monoamine transporter 2 (VMAT 2) in comparison with the 
pathologically normal subjects; the reductions were even greater in those with PD. Also, SN 
neuronal loss correlated with both striatal VMAT2 and TH. Thus, ILBD probably represents 
presymptomatic PD rather than nonspecific, age-related alpha-synuclein pathological 
changes.  
In PD, approximately 60% of the nigrostrial neurons of the SN are degenerated before 
patients fulfill the clinical criteria of PD (Fearnkey et al., 1991). In some cases of PD, the 
patient appears to develop cortical disease before the motor signs of “stage 3” disease, 
whereas iRBD patients with ILBD could be diagnosed after longstanding disease with no 
evidence of motor or cognitive abnormalities (Uchiyama et al., 1995; Boeve et al., 2007). If 
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progression of syncleinopathies is not universal, it is essential to understand why. Since a 
variety of symptoms of PD and disorders resembling PD have been elucidated, Langston 
(Langston et al., 2006) proposed a “Parkinson’s complex” because parkinsonism would 
represent only the tip of the iceberg as typically viewed by both clinicians and researchers. 
However, when the disease process is measured by neuronal degeneration, the presence of 
Lewy bodies and neuritic pathology are widespread in the central and peripheral nervous 
systems. From this point of view, iRBD can be positioned as an earlier preclinical stage of 
PD or DLB or a variant of Lewy body-related alpha-synucleinopathies. To gain such an 
understanding, it is necessary to extract a group of patients with abnormalities in a 
combination of markers from among iRBD patients and provide follow-up, considering the 
possibility that some patients in that group may develop neurodegenerative disease (Figure 
6). These steps may help elucidate the possibility that iRBD is part of the spectrum of 
conditions under the heading of alpha-synucleinopathies, such as PD, DLB, or MSA, or is a 
subtype of Lewy body-related alpha-synucleinopathy.  
 
 
Fig. 6. Combinations of markers for neurodegenerative disease in patients idiopathic REM 
sleep behavior disorder. A longitudinal study of a large cohort of patients with RBD should 
identify which marker or combination of makers can predict progression toward a 
neurodegenerative disorder. The question is, does iRBD progress insidiously to PD, DLB or 
MSA, or does it remain static? 
MCI, mild cognitive impairment, AD, Alzheimer disease, PSP, progressive supranuclear 
palsy, CBD, corticobasal degeneration, DLB, dementia with Lewy bodies, PD, Parkinson’s 
disease, MSA, multiple system atrophy, SCD, spinocerebellar degeneration, iRBD, 
idiopathic REM sleep behaviour disorder. 
DLB*PSP +
* synucleinopathies
AD+
CBD +
PD*
Parkinsonism
Autonomic failure
Lewy body synucleinopathies
MSA*
SCD
Reduced smell identification
Reduced MIBG uptake
Substantia nigra
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Dementia
+ taunopathy
REM sleep behavior disorder
REM sleep without atonia
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10. Conclusion 
Combinations of markers in iRBD were considered for the purpose of diagnosing 
neurodegenerative diseases such as PD, DLB or MSA at an early stage. Important advances 
have been made in the diagnosis of PD using imaging methods such as PET/SPECT or 
cardiac 123I-MIBG scintigraphy. However, while these methods are important in clinical 
research, they are complex, expensive, not widely available and inappropriate for the 
routine screening of large populations. Recent advances in the identification of biomarkers 
in iRBD offer diagnostic opportunities and point the way to new therapeutic strategies.    
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